Sanchez Ramiro 4
4 · Rapport Therapeutics, Inc. · Filed Jun 10, 2026
Research Summary
AI-generated summary of this filing
Rapport Therapeutics (RAPP) Director Sanchez Ramiro Receives Award
What Happened Sanchez Ramiro, a director of Rapport Therapeutics, was granted a derivative award covering 15,200 shares on 2026-06-10. The Form 4 reports an acquisition price of $0.00 for the award (transaction code A), indicating a grant of equity-based compensation rather than an open-market purchase or sale.
Key Details
- Transaction date and price: 2026-06-10; reported acquisition price $0.00 (grant/award).
- Shares acquired: derivative award for 15,200 shares.
- Shares owned after transaction: not disclosed in this filing.
- Footnote: the shares underlying this award vest upon the earlier of (i) June 10, 2027, or (ii) the date of the next Annual Meeting of Stockholders, subject to the Reporting Person’s continued service.
- Filing timeliness: reported on 2026-06-10 (appears timely; no late-filing flag shown).
Context This filing documents an equity grant (derivative award), not an immediate purchase or sale. Such awards are common for board compensation and align insiders’ interests with shareholders over the vesting period; they do not indicate an immediate change in market holdings or a sale of stock.
Insider Transaction Report
Form 4
Sanchez Ramiro
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-06-10+15,200→ 15,200 totalExercise: $35.21Exp: 2036-06-10→ Common Stock (15,200 underlying)
Footnotes (1)
- [F1]The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
Signature
/s/ Troy Ignelzi, Attorney-in-Fact|2026-06-10